Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1468

1.

A Bayesian approach to probabilistic sensitivity analysis in structured benefit-risk assessment.

Waddingham E, Mt-Isa S, Nixon R, Ashby D.

Biom J. 2015 Jan 28. doi: 10.1002/bimj.201300254. [Epub ahead of print]

PMID:
25631038
[PubMed - as supplied by publisher]
2.

Neuropsychological impairment in natalizumab-associated progressive multifocal leukoencephalopathy: implications for early diagnosis.

Hoepner R, Klotz P, Faissner S, Schneider R, Kinner M, Prehn C, Gold R, Chan A.

J Neurol Neurosurg Psychiatry. 2015 Jan 27. pii: jnnp-2014-310287. doi: 10.1136/jnnp-2014-310287. [Epub ahead of print] No abstract available.

PMID:
25628377
[PubMed - as supplied by publisher]
3.

Multiple sclerosis: IgM bands indicate reduced risk of PML on natalizumab.

[No authors listed]

Nat Rev Neurol. 2015 Jan 27. doi: 10.1038/nrneurol.2014.266. [Epub ahead of print] No abstract available.

PMID:
25623786
[PubMed - as supplied by publisher]
4.

[Vedolizumab in the treatment of Crohn's disease.]

Gisbert JP, Domènech E.

Gastroenterol Hepatol. 2015 Jan 22. pii: S0210-5705(14)00321-5. doi: 10.1016/j.gastrohep.2014.12.003. [Epub ahead of print] Spanish.

PMID:
25619903
[PubMed - as supplied by publisher]
5.

A case study using the PrOACT-URL and BRAT frameworks for structured benefit risk assessment.

Nixon R, Dierig C, Mt-Isa S, Stöckert I, Tong T, Kuhls S, Hodgson G, Pears J, Waddingham E, Hockley K, Thomson A.

Biom J. 2015 Jan 26. doi: 10.1002/bimj.201300248. [Epub ahead of print]

PMID:
25619173
[PubMed - as supplied by publisher]
6.

Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy.

Clausi V, Giannecchini S, Magnani E, Repice A, Mechi C, Martelli F, Azzi A, Massacesi L.

Neurol Neuroimmunol Neuroinflamm. 2015 Jan 14;2(1):e58. doi: 10.1212/NXI.0000000000000058. eCollection 2015 Feb.

PMID:
25610882
[PubMed]
Free PMC Article
7.

Natalizumab in MS: JC antibody index.

Fung W, Robertson NP.

J Neurol. 2015 Jan 22. [Epub ahead of print] No abstract available.

PMID:
25605436
[PubMed - as supplied by publisher]
8.

High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc.

Stork L, Brück W, Bar-Or A, Metz I.

Acta Neuropathol. 2015 Jan 22. [Epub ahead of print] No abstract available.

PMID:
25604548
[PubMed - as supplied by publisher]
9.

High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis.

Harrer A, Pilz G, Wipfler P, Oppermann K, Sellner J, Hitzl W, Haschke-Becher E, Afazel S, Rispens T, van der Kleij D, Trinka E, Kraus J.

Clin Exp Immunol. 2015 Jan 20. doi: 10.1111/cei.12590. [Epub ahead of print]

PMID:
25603898
[PubMed - as supplied by publisher]
10.

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.

Antoniol C, Stankoff B.

Front Immunol. 2015 Jan 5;5:668. doi: 10.3389/fimmu.2014.00668. eCollection 2014. Review.

PMID:
25601865
[PubMed]
Free PMC Article
11.

The importance of mouse models to define immunovirologic determinants of progressive multifocal leukoencephalopathy.

Frost EL, Lukacher AE.

Front Immunol. 2015 Jan 5;5:646. doi: 10.3389/fimmu.2014.00646. eCollection 2014. Review.

PMID:
25601860
[PubMed]
Free PMC Article
12.

Natalizumab discontinuation and disease restart in pregnancy: a case series.

De Giglio L, Gasperini C, Tortorella C, Trojano M, Pozzilli C.

Acta Neurol Scand. 2015 Jan 18. doi: 10.1111/ane.12364. [Epub ahead of print]

PMID:
25598313
[PubMed - as supplied by publisher]
13.

Immunomodulatory characteristics of mesenchymal stem cells and their role in the treatment of Multiple Sclerosis.

Gharibi T, Ahmadi M, Seyfizadeh N, Jadidi-Niaragh F, Yousefi M.

Cell Immunol. 2015 Jan 10;293(2):113-121. doi: 10.1016/j.cellimm.2015.01.002. [Epub ahead of print] Review.

PMID:
25596473
[PubMed - as supplied by publisher]
14.

Multiple sclerosis in children and adolescents. An important differential diagnosis of acute neurological disease.

Sandvig I, Barlinn J, Nedregaard B, Skjeldal OH.

Eur J Paediatr Neurol. 2014 Dec 30. pii: S1090-3798(14)00205-0. doi: 10.1016/j.ejpn.2014.12.004. [Epub ahead of print]

PMID:
25596063
[PubMed - as supplied by publisher]
15.

[The first Russian experience of using natalizumab in the treatment of relapsing-remitting multiple sclerosis in children.]

Sivertseva SA, Levitina EV, Traĭkhil' AM, Zakateĭ IG, Bazhukhin DV, Sivertsev MI, Smirnova NF, Boĭko AN.

Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(10 Vypusk 2 Rasseiannyi skleroz):92-98. Russian. No abstract available.

PMID:
25591539
[PubMed - as supplied by publisher]
16.

Transfer of Natalizumab into Breast Milk in a Mother with Multiple Sclerosis.

Baker TE, Cooper SD, Kessler L, Hale TW.

J Hum Lact. 2015 Jan 13. pii: 0890334414566237. [Epub ahead of print]

PMID:
25586712
[PubMed - as supplied by publisher]
17.

Therapeutic interference with leukocyte recirculation in multiple sclerosis.

Sellebjerg F, Sørensen PS.

Eur J Neurol. 2015 Jan 13. doi: 10.1111/ene.12668. [Epub ahead of print]

PMID:
25582213
[PubMed - as supplied by publisher]
18.

lipid-specific IgM bands in csf associated with a reduced risk of developing pml during treatment with natalizumab.

Villar LM, Costa-Frossard L, Masterman T, Fernandez O, Montalban X, Casanova B, Izquierdo G, Coret F, Tumani H, Saiz A, Arroyo R, Fink K, Leyva L, Espejo C, Simó-Castelló M, García-Sánchez MI, Lauda F, Llufriú S, Álvarez-Lafuente R, Olascoaga J, Prada A, Oterino A, de Andrés C, Tintoré M, Ramió-Torrentà L, Rodríguez-Martín E, Picón C, Comabella M, Quintana E, Agüera E, Díaz S, Fernandez-Bolaños R, García-Merino JA, Landete L, Menéndez-González M, Navarro L, Pérez D, Sánchez-López F, Serrano-Castro PJ, Tuñón A, Espiño M, Muriel A, Bar-Or A, Álvarez-Cermeño JC.

Ann Neurol. 2015 Jan 7. doi: 10.1002/ana.24345. [Epub ahead of print]

PMID:
25581547
[PubMed - as supplied by publisher]
19.

Risk of infections of biological therapies with accent on inflammatory bowel disease.

Nanau RM, Cohen LE, Neuman MG.

J Pharm Pharm Sci. 2014 Oct-Dec;17(4):485-531.

PMID:
25579431
[PubMed - in process]
20.

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, Lechner-Scott J, Slee M, Fernandez-Bolanos R, Grand'Maison F, Hupperts R, Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R, McCombe P, Sanchez-Menoyo J, Simo M, Csepany T, Rum G, Boz C, Havrdova E, Butzkueven H; on behalf of the MSBase Study Group.

Ann Neurol. 2014 Dec 27. doi: 10.1002/ana.24339. [Epub ahead of print]

PMID:
25546031
[PubMed - as supplied by publisher]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk